OBJECTIVE: The purpose of this work was to investigate the influence of age, gender, and antiepileptic therapy on amino acid cerebrospinal fluid/plasma ratios in children. PATIENTS AND METHODS: Concentrations of 17 amino acids measured by ion-exchange chromatography with ninhydrin detection in plasma and cerebrospinal fluid from 68 patients with neurologic diseases were used to calculate their cerebrospinal fluid/plasma ratios (70 measurements; 28 female patients [29 punctures] and 40 male patients [41 punctures]). Age dependence and the effects of gender and antiepileptic medication on amino acid cerebrospinal fluid/plasma ratios were investigated by linear multiple regression analysis, and nonstandardized predicted mean values for 2 age groups were calculated (cutoff: 3 years old). RESULTS: The cerebrospinal fluid/plasma ratios ranged between 0.02 for glycine and 0.93 for glutamine. Age had a significant influence on cerebrospinal fluid/plasma ratios for valine, isoleucine, leucine, and tyrosine, with higher ratios in younger children. Gender had a significant influence only on the glutamine cerebrospinal fluid/plasma ratio (female patients had lower ratios). Cerebrospinal fluid/plasma ratios of glutamine and tyrosine were significantly elevated by valproate therapy and those of serine, asparagine, glutamine, valine, methionine, and phenylalanine by phenobarbital therapy. No significant influence of age, gender, and antiepileptic drugs was detectable on cerebrospinal fluid/plasma ratios of threonine, proline, glycine, alanine, histidine, ornithine, lysine, and arginine. CONCLUSIONS: Cerebrospinal fluid/plasma ratios, especially for essential neutral amino acids and for serine, asparagine, and glutamine were influenced to different degrees by age, gender, and antiepileptic therapy.
OBJECTIVE: The purpose of this work was to investigate the influence of age, gender, and antiepileptic therapy on amino acid cerebrospinal fluid/plasma ratios in children. PATIENTS AND METHODS: Concentrations of 17 amino acids measured by ion-exchange chromatography with ninhydrin detection in plasma and cerebrospinal fluid from 68 patients with neurologic diseases were used to calculate their cerebrospinal fluid/plasma ratios (70 measurements; 28 female patients [29 punctures] and 40 male patients [41 punctures]). Age dependence and the effects of gender and antiepileptic medication on amino acid cerebrospinal fluid/plasma ratios were investigated by linear multiple regression analysis, and nonstandardized predicted mean values for 2 age groups were calculated (cutoff: 3 years old). RESULTS: The cerebrospinal fluid/plasma ratios ranged between 0.02 for glycine and 0.93 for glutamine. Age had a significant influence on cerebrospinal fluid/plasma ratios for valine, isoleucine, leucine, and tyrosine, with higher ratios in younger children. Gender had a significant influence only on the glutamine cerebrospinal fluid/plasma ratio (female patients had lower ratios). Cerebrospinal fluid/plasma ratios of glutamine and tyrosine were significantly elevated by valproate therapy and those of serine, asparagine, glutamine, valine, methionine, and phenylalanine by phenobarbital therapy. No significant influence of age, gender, and antiepileptic drugs was detectable on cerebrospinal fluid/plasma ratios of threonine, proline, glycine, alanine, histidine, ornithine, lysine, and arginine. CONCLUSIONS: Cerebrospinal fluid/plasma ratios, especially for essential neutral amino acids and for serine, asparagine, and glutamine were influenced to different degrees by age, gender, and antiepileptic therapy.
Authors: Rabindra Tirouvanziam; Tetyana V Obukhanych; Julie Laval; Pavel A Aronov; Robin Libove; Arpita Goswami Banerjee; Karen J Parker; Ruth O'Hara; Leonard A Herzenberg; Leonore A Herzenberg; Antonio Y Hardan Journal: J Autism Dev Disord Date: 2012-05
Authors: Stephanie J Sacharow; Elizabeth E Dudenhausen; Carrie L Lomelino; Lance Rodan; Christelle Moufawad El Achkar; Heather E Olson; Casie A Genetti; Pankaj B Agrawal; Robert McKenna; Michael S Kilberg Journal: Mol Genet Metab Date: 2017-12-20 Impact factor: 4.797
Authors: Alan M Smith; Joseph J King; Paul R West; Michael A Ludwig; Elizabeth L R Donley; Robert E Burrier; David G Amaral Journal: Biol Psychiatry Date: 2018-09-06 Impact factor: 13.382
Authors: Diego Martinelli; Johannes Häberle; Vicente Rubio; Cecilia Giunta; Ingrid Hausser; Rosalba Carrozzo; Nadine Gougeard; Clara Marco-Marín; Bianca M Goffredo; Maria Chiara Meschini; Elsa Bevivino; Sara Boenzi; Giovanna Stefania Colafati; Francesco Brancati; Matthias R Baumgartner; Carlo Dionisi-Vici Journal: J Inherit Metab Dis Date: 2011-12-15 Impact factor: 4.982
Authors: S Scholl-Bürgi; S Baumgartner Sigl; J Häberle; E Haberlandt; K Rostásy; C Ertl; U Eichinger-Öttl; P Heinz-Erian; D Karall Journal: J Inherit Metab Dis Date: 2008-12-06 Impact factor: 4.982
Authors: Elizabeth K Ruzzo; José-Mario Capo-Chichi; Bruria Ben-Zeev; David Chitayat; Hanqian Mao; Andrea L Pappas; Yuki Hitomi; Yi-Fan Lu; Xiaodi Yao; Fadi F Hamdan; Kimberly Pelak; Haike Reznik-Wolf; Ifat Bar-Joseph; Danit Oz-Levi; Dorit Lev; Tally Lerman-Sagie; Esther Leshinsky-Silver; Yair Anikster; Edna Ben-Asher; Tsviya Olender; Laurence Colleaux; Jean-Claude Décarie; Susan Blaser; Brenda Banwell; Rasesh B Joshi; Xiao-Ping He; Lysanne Patry; Rachel J Silver; Sylvia Dobrzeniecka; Mohammad S Islam; Abul Hasnat; Mark E Samuels; Dipendra K Aryal; Ramona M Rodriguiz; Yong-Hui Jiang; William C Wetsel; James O McNamara; Guy A Rouleau; Debra L Silver; Doron Lancet; Elon Pras; Grant A Mitchell; Jacques L Michaud; David B Goldstein Journal: Neuron Date: 2013-10-16 Impact factor: 17.173
Authors: Ralf Geiger; Benedikt Treml; Anna Pinna; Linn Barnickel; Harald Prossliner; Hannes Reinstadler; Michael Pilch; Maria Hauer; Christoph Walther; Hans-Jörg Steiner; Thomas Giese; Andreas Wemhöner; Sabine Scholl-Bürgi; Waldemar Gottardi; Roland Arnitz; Consolato Sergi; Markus Nagl; Alexander Löckinger Journal: BMC Pulm Med Date: 2009-07-14 Impact factor: 3.317
Authors: Austin L Brown; Pagna Sok; Olga Taylor; John P Woodhouse; M Brooke Bernhardt; Kimberly P Raghubar; Lisa S Kahalley; Philip J Lupo; Marilyn J Hockenberry; Michael E Scheurer Journal: J Pain Symptom Manage Date: 2020-09-01 Impact factor: 3.612